Published in Oncogene on September 29, 2003
Cyclin T1 overexpression induces malignant transformation and tumor growth. Cell Cycle (2010) 2.38
Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A (2005) 2.10
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood (2008) 1.52
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol (2010) 1.33
Werner protein protects nonproliferating cells from oxidative DNA damage. Mol Cell Biol (2005) 1.26
Fusobacterium nucleatum increases collagenase 3 production and migration of epithelial cells. Infect Immun (2005) 1.24
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res (2012) 1.20
Cdk1 and Cdk2 activity levels determine the efficiency of replication origin firing in Xenopus. EMBO J (2008) 1.16
p53 and retinoblastoma pathways in bladder cancer. World J Urol (2007) 1.16
A bifunctional regulatory element in human somatic Wee1 mediates cyclin A/Cdk2 binding and Crm1-dependent nuclear export. Mol Cell Biol (2010) 1.10
Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A (2004) 1.08
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res (2009) 1.08
A systems biology dynamical model of mammalian G1 cell cycle progression. Mol Syst Biol (2007) 1.05
Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer (2005) 0.99
Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer (2006) 0.96
Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids (2007) 0.95
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro Oncol (2005) 0.93
Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity. Oncogene (2006) 0.91
Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast. J Pathol (2009) 0.91
Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agents. Inorg Chem (2011) 0.89
Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development. ISRN Oncol (2013) 0.84
Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells. J Cancer (2011) 0.84
Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues. Invest New Drugs (2008) 0.82
Mammalian interphase cdks: dispensable master regulators of the cell cycle. Genes Cancer (2012) 0.82
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica (2009) 0.81
The molecular genetics of breast cancer and targeted therapy. Biologics (2007) 0.81
Targeted therapies in the management of metastatic bladder cancer. Biologics (2007) 0.79
Estrogen-related receptor γ is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27. Exp Mol Med (2016) 0.77
Derricin and derricidin inhibit Wnt/β-catenin signaling and suppress colon cancer cell growth in vitro. PLoS One (2015) 0.77
Homeostatic response under carcinogen withdrawal, heme oxygenase 1 expression and cell cycle association. BMC Cancer (2006) 0.76
Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J Biol Chem (2011) 0.75
Regulation of the human papillomavirus type 16 late promoter by transcriptional elongation. Virology (2017) 0.75
Staurosporine and extracellular matrix proteins mediate the conversion of small cell lung carcinoma cells into a neuron-like phenotype. PLoS One (2014) 0.75
Effects of Auraptene on IGF-1 Stimulated Cell Cycle Progression in the Human Breast Cancer Cell Line, MCF-7. Int J Breast Cancer (2012) 0.75
Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PLoS One (2016) 0.75
Cell cycle modulators for the treatment of lung malignancies. Clin Lung Cancer (2003) 0.85